更新于：2024-05-01

Nasal Polyps

鼻息肉

更新于：2024-05-01

基本信息

别名

NASAL POLYP、NASAL POLYPOSIS、NOSE POLYP

+ [56]

简介

Focal accumulations of EDEMA fluid in the NASAL MUCOSA accompanied by HYPERPLASIA of the associated submucosal connective tissue. Polyps may be NEOPLASMS, foci of INFLAMMATION, degenerative lesions, or malformations.

关联

项与鼻息肉相关的药物

Tezepelumab

靶点

TSLP

作用机制

TSLP抑制剂

在研机构

原研机构

在研适应症

非在研适应症

最高研发阶段批准上市

首次获批国家/地区

美国

首次获批日期2021-12-17

Rimegepant Sulfate

硫酸瑞美吉泮

靶点

CGRP receptor

作用机制

CALCRL拮抗剂

在研机构

原研机构

在研适应症

非在研适应症

最高研发阶段批准上市

首次获批国家/地区

美国

首次获批日期2020-02-27

Benralizumab

贝那利珠单抗

靶点

IL-5Rα

作用机制

IL-5Rα抑制剂

在研机构

原研机构

在研适应症

非在研适应症

最高研发阶段批准上市

首次获批国家/地区

美国

首次获批日期2017-11-14

313

项与鼻息肉相关的临床试验

NCT06372678 / Not yet recruiting临床2期

A Randomized, Double-blind, Placebo-controlled Phase II Study to Evaluate the Efficacy and Safety of CM326 in Participants With Chronic Rhinosinusitis With Nasal Polyposis

This is a multi-center, randomized, double blind, placebo-controlled Phase II study to evaluate the efficacy and safety of CM326, and to observe the Pharmacokinetics, Pharmacodynamics and immumogenicity of CM326 in patients with chronic rhinosinusitis with nasal polyposis (CRSwNP).

开始日期2024-06-30

申办/合作机构-

NCT06182982 / Not yet recruitingN/AIIT

Efficacy of Auriculotherapy Medical Devices in Intraoperative Blood Pressure Control During Endoscopic Sinus Surgery, a Prospective Randomized Controlled Study.

The endoscopic surgery of the paranasal sinuses (FESS) requires careful control of arterial pressure to prevent bleeding of the nasal mucosa that may lead to a reduction in the visual field. However, controlled reversible hypotension has been associated with phenomena of peripheral hypoperfusion with possible organ damage on an ischemic basis. Based on the data available in the literature, a mean arterial pressure (MAP) target between 50 and 65 mmHg is considered acceptable. Although blood pressure control is generally ensured through intravenous pharmacological approaches, there is evidence of efficacy with the use of Auriculotherapy medical devices (stimulation of specific points in the ear through the application of Magnetic ball plasters).
Proposed pharmacological choices to achieve this result have been multiple, although totally intravenous anesthesia with propofol and opioids seems to be more effective than balanced anesthesia with halogenated agents and opioids. However, this fundamental option requires the administration of antihypertensive drugs to achieve the blood pressure target. Despite common contraindications to individual pharmacological classes, various active principles have been compared. Among these, continuous low-dose nitroglycerin infusion has proven effective due to titratability linked to its short half-life, perioperative complications, and better conditions of peripheral perfusion compared to beta-blockers such as labetalol or esmolol.
Based on existing literature data, in our hospital, general anesthesia is typically conducted with intravenous techniques and the continuous administration of low doses of nitroglycerin in continuous infusion (0.01-2 mcg/kg/min). Despite the low dosages, this drug can be burdened with dosage-dependent adverse effects such as orthostatic hypotension, tachycardia, or headache. To reduce the dosage of nitroglycerin, we have borrowed from different contexts hypotensive auriculotherapy techniques (stimulation of specific ear points through the application of magnetic ball plasters), which have proven effective in managing systemic pressure in patients with essential hypertension.
These non-pharmacological techniques, already used during general anesthesia for the management of nausea and pain, could prove promising in reducing the use of antihypertensive drugs even in the intraoperative context. The primary hypothesis of our study is that the use of Auriculotherapy medical devices is effective in achieving a hypotensive effect in patients undergoing general anesthesia during FESS surgery.

开始日期2024-06-15

申办/合作机构-

NCT06338995 / Not yet recruiting临床3期

A Multicentre, Randomized, Double-blind, Placebo-controlled, Parallel Group Phase 3 Efficacy and Safety Study of Lebrikizumab/ LY3650150 in Adults With Chronic Rhinosinusitis With Nasal Polyps on a Background Therapy With Intranasal Corticosteroids

The main purpose of this study is to evaluate the efficacy and safety of lebrikizumab in adult participants with chronic rhinosinusitis and nasal polyps treated with intranasal corticosteroids. The study will last about 18 months.

开始日期2024-04-10

申办/合作机构

Eli Lilly & Co.

100 项与鼻息肉相关的临床结果

登录后查看更多信息

100 项与鼻息肉相关的转化医学

登录后查看更多信息

0 项与鼻息肉相关的专利（医药）

登录后查看更多信息

8,381

项与鼻息肉相关的文献（医药）

2024-05-01·The journal of allergy and clinical immunology. Global

Aspirin-exacerbated respiratory disease is associated with variants in filaggrin, epithelial integrity, and cellular interactions.

Article

作者: Elina Jerschow ; Robert Dubin ; Chien-Chang Chen ; Alex iAkushev ; Esha Sehanobish ; Mohammad Asad ; Sergio E Chiarella ; Steven A Porcelli ; John Greally

Background:

Previous studies have determined that up to 6% of patients with aspirin-exacerbated respiratory disease (AERD) have family history of AERD, indicating a possible link with genetic polymorphisms. However, whole exome sequencing (WES) studies of such associations are currently lacking.

Objectives:

We sought to examine whether WES can identify pathogenic variants associated with AERD.

Methods:

Diagnoses of AERD were confirmed in patients with nasal polyps and asthma. WES was performed using an Illumina sequencing platform. Human Phenotype Ontology terms were used to define the patients' phenotypes. Exomiser was used to annotate, filter, and prioritize possible disease-causing genetic variants.

Results:

Of 39 patients with AERD, 41% reported a family history of asthma and 5% reported a family history of AERD. Pathogenic exome variants in the filaggrin gene (FLG) were found in 2 patients (5%). Other variants not known to be pathogenic were detected in an additional 16 patients (41%) in genes related to epithelial integrity and cellular interactions, including genes encoding desmoglein 3 (DSG3), dynein axonemal heavy chain 9 (DNAH9), collagen type VII alpha 1 chain (COL7A1), collagen type XVII alpha 1 chain (COL17A1), chromodomain helicase DNA binding protein-7 (CHD7), TSC complex subunit 2/tuberous sclerosis-2 protein (TSC2), P-selectin (SELP), and platelet-derived growth factor receptor-alpha (PDGFRA).

Conclusion:

WES identified a monogenic susceptibility to AERD in 5% of patients with FLG pathogenic variants. Other variants not previously identified as pathogenic were found in genes relevant to epithelial integrity and cellular interactions and may further reveal genetic factors that contribute to this condition.

2024-02-23·Inflammation research : official journal of the European Histamine Research Society ... [et al.]

Interleukin-19 enhances eosinophil infiltration through upregulation of epithelium-derived RANTES expression via the ERK/NF-κB signalling pathway in patients with eosinophilic CRSwNP.

Article

作者: Zizhen Huang ; Xia Li ; Yue Li ; Weiqiang Huang ; Xiaoping Lai ; Haotian Wu ; Xiaohong Chen ; Yana Zhang ; Lihong Chang ; Gehua Zhang

BACKGROUD:

The recurrence rate of chronic rhinosinusitis with nasal polyps (CRSwNP) is positively correlated with eosinophil infiltration. Increased interleukin (IL)-19 and eosinophil chemokine RANTES levels have been reported in patients with CRSwNP. This study aimed to clarify the role of IL-19 in mediating RANTES expression and eosinophilic infiltration in eosinophilic CRSwNP (Eos CRSwNP).

METHODS:

Nasal tissue samples were obtained from patients with CRSwNP and controls. The expression of IL-19, its receptors, ECP, and RANTES in tissues was investigated. Primary human nasal epithelial cells (HNECs) and nasal polyp tissue blocks were cultured, then stimulated by IL-19; ERK phosphorylation, NF-κB pathway activation, RANTES level, eosinophils migration and infiltration were detected using RT-qPCR, ELISA, western blotting, HE, immunohistochemistry, immunofluorescence staining, confocal microscopy, and transwell migration assay.

RESULTS:

The expression of IL-19 and its receptors (IL-20R1/IL-20R2), eosinophil cationic protein, and RANTES in nasal tissues from patients with Eos CRSwNP was significantly increased compared to that in non-Eos CRSwNP and control subjects. IL-19 co-localized with RANTES in nasal tissues and significantly elevated RANTES expression in HNECs. IL-19-blocking antibody and siRNA knockdown of IL-20R1 ameliorated the effect of IL-19 on RANTES secretion in HNECs. Moreover, IL-19-induced RANTES upregulation was associated with the activation of the ERK and NF-κB pathways. NF-κB activation was mediated by the ERK pathway in IL-19-treated HNECs, and IL-19 enhanced eosinophil infiltration in nasal polyp tissue blocks.

CONCLUSIONS:

Our findings indicate that IL-19 promotes RANTES expression via the ERK/NF-κB pathway in HNECs and is implicated in eosinophil infiltration in patients with Eos CRSwNP.

2024-02-22·The Journal of allergy and clinical immunology

Bronchiectasis and asthma: Data from The European Bronchiectasis Registry (EMBARC).

Article

作者: Eva Polverino ; Katerina Dimakou ; Letizia Traversi ; Apostolos Bossios ; Charles S Haworth ; Michael R Loebinger ; Anthony De Soyza ; Montserrat Vendrell ; Pierre-Régis Burgel ; Pontus Mertsch ; Melissa McDonnell ; Sabina Škrgat ; Luis M Carro ; Oriol Sibila ; Menno van der Eerden ; Paula Kauppi ; Adam T Hill ; Robert Wilson ; Branislava Milenkovic ; Rosario Menendez ; Marlene Murris ; Tonia Digalaki ; Megan L Crichton ; Sermin Borecki ; Dusanka Obradovic ; Adam Nowinski ; Adelina Amorim ; Antoni Torres ; Natalie Lorent ; Tobias Welte ; Francesco Blasi ; Eva Van Braeckel ; Josje Altenburg ; Amelia Shoemark ; Michal Shteinberg ; Wim Boersma ; J Stuart Elborn ; Stefano Aliberti ; Felix C Ringshausen ; James D Chalmers ; Pieter C Goeminne ; EMBARC registry investigators

BACKGROUND:

Asthma is commonly reported in patients with a diagnosis of bronchiectasis.

OBJECTIVE:

The aim of this study was to evaluate if patients with asthma and bronchiectasis had a different clinical phenotype and different outcomes compared to patients with bronchiectasis without concomitant asthma.

METHODS:

Prospective observational pan-European registry (EMBARC) enrolling patients across 28 countries. Adult patients with CT confirmed bronchiectasis were reviewed at baseline and annual follow-up visits using an electronic case report form. Asthma was diagnosed by the local investigator. Follow-up data were used to explore differences in exacerbation frequency between groups using a negative binomial regression model. Survival analysis utilised Cox-proportional hazards regression.

RESULTS:

16963 patients with bronchiectasis were included for analysis. 5267 patients (31.0%) had investigator reported asthma. Patients with bronchiectasis and asthma (BE+A) were younger, more likely to be female and never smokers, and had a higher BMI than patients with bronchiectasis without asthma. BE+A was associated with a higher prevalence of rhinosinusitis and nasal polyps as well as eosinophilia and Aspergillus sensitization. BE+A had similar microbiology, but significantly lower severity of disease using the bronchiectasis severity index (BSI). The BE+A group were at increased risk of exacerbation after adjustment for severity of disease and multiple confounders. Inhaled corticosteroid use was associated with reduced mortality in BE+A patients (adjusted hazard ratio 0.78 (0.63-0.95)) and reduced risk of hospitalization, (rate ratio 0.67 (0.67-0.86)) compared to a control population without asthma and not receiving inhaled corticosteroid.

CONCLUSION:

Combined bronchiectasis and asthma was common and was associated with an increased risk of exacerbations and improved outcomes with inhaled corticosteroid use. Unexpectedly we identified significantly lower mortality in patients with bronchiectasis and asthma.

410

项与鼻息肉相关的新闻（医药）

2024-04-05

·Pharmaceutical Technology

GSK expands Asia-Pacific reach for Trelegy Ellipta with Singapore approval

Trelegy Ellipta is approved as a maintenance treatment for COPD and asthma in the US. Image Credit: MAXSHOT.PL / Shutterstock. Singapore’s Health Sciences Authority (HSA) has expanded the label of GlaxoSmithKline (GSK)’s Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol) to include its use as a maintenance therapy for adults with asthma. The Singapore agency also approved a new dosage strength for the inhaled therapy in asthma. In 2019, HSA approved Trelegy Ellipta as a maintenance therapy for relieving moderate to severe exacerbations in patients with chronic obstructive pulmonary disease (COPD). Trelegy Ellipta is approved as a maintenance treatment for COPD in multiple regions including the US, Europe and China. However, the drug has also been approved for treating asthma in a few countries such as the US. Trelegy Ellipta pulled in £2.2bn ($2.8bn) in global sales for GSK in 2023, as per the company’s financials. The drug sales are expected to rise, with Trelegy Ellipta expected to generate approximately $3.8bn in global sales in 2027, according to a GlobalData analysis. GlobalData is the parent company of Pharmaceutical Technology . Last month, GSK announced plans to cap out-of-pocket costs for eligible patients at $35 per month for its COPD and asthma medications in light of the rising drug prices in the US. Trelegy Ellipta is one of the drugs included in GSK’s programme, which will be implemented across the country no later than 1 January 2025. See Also: UK MHRA approves Advanz Pharma antibiotic for complex infections Japan’s PMDA approves Partner’s inhaled Leukine for aPAP Another therapy looking to target both asthma and COPD populations is Amgen and AstraZeneca ’s Tezspire (tezepelumab-ekko). The monoclonal antibody has been approved for treating severe asthma in multiple countries including the US. The companies are evaluating the therapy in patients with moderate to severe COPD in a placebo-controlled Phase II trial (NCT04039113). Data from the trial is expected in H1 this year. Regeneron Pharmaceuticals and Sanofi are also seeking approval for their monoclonal antibody , Dupixent (dupilumab) as a maintenance therapy for COPD. The US Food and Drug Administration (FDA) has set a target action date of 27 June for an approval decision. Dupixent is approved for treating atopic dermatitis , asthma, chronic rhinosinusitis with nasal polyposis, eosinophilic esophagitis and prurigo nodularis.

上市批准临床2期

2024-04-02

·药研发

【药研发0403】徐诺中美双报抗癌药获批IND | 恒赛中美双报肿瘤疫苗获批IND...

「本文共：15条资讯，阅读时长约：3分钟」今日头条徐诺中美双报抗癌药获批IND。徐诺药业新一代广谱RAF抑制剂XP-102获国家药监局批准开展Ⅰ期临床，拟评估用于治疗BRAF V600突变阳性的晚期实体瘤患者的安全性、耐受性、药代动力学和初步疗效，预计今年完成患者入组。多项临床前研究显示，XP-102可能恢复耐药肿瘤的药物敏感性，有望为肿瘤耐药患者提供新的治疗方案。目前，XP-102正在美国开展Ⅰ/Ⅱa期临床试验。国内药讯1.成都倍特司美格鲁肽启动Ⅲ期临床。倍特药业3.3类新药司美格鲁肽注射液在Clinicaltrials.gov网站上注册一项Ⅲ期临床，拟评估与诺和诺德司美格鲁肽注射液Ozempic头对头比较，治疗2型糖尿病的有效性和安全性。今年3月，该产品获NMPA批准新IND，适应症为“作为低卡路里饮食和增加体力活动的辅助治疗用于肥胖或超重并且伴有至少一种与超重相关的合并症的成人患者”。2.上海正序地贫基因编辑疗法获批IND。正序生物碱基编辑药物“CS-101注射液”获国家药监局临床许可，拟用于重型β-地中海贫血的治疗。在研究者发起的临床试验（IIT）中，CS-101已成功治愈首例重型β-地中海贫血症患者，达到持续摆脱输血依赖超过两个月，治疗后8周，患者的胎儿血红蛋白浓度上升至95 g/L，比例上升至81%，表达胎儿血红蛋白的F细胞比例上升至80%。3.辉瑞2款自免三抗中国报IND。辉瑞炎症与免疫学领域1类生物药PF-07264660注射液和PF-07275315注射液的临床试验申请获NMPA受理。研究发现，IL-13和IL-4是诱导和维持2型炎症反应的关键细胞因子，与多种特应性疾病如特异性皮炎（AD）、哮喘和慢性鼻窦炎伴鼻息肉病（CSwNP）等有关。PF-07275315是一款IL-4/IL-13/TSLP三抗，PD-07264660是IL-4/IL-13/IL-33三抗，两款新药目前正分别在Ⅱ期临床中评估用于治疗特应性皮炎的潜力。4.恒赛中美双报肿瘤疫苗获批IND。恒赛生物首发管线KSD-101获FDA批准开展新药临床试验。KSD-101是负载EB病毒相关类肿瘤复合抗原的人单核细胞来源自体树突细胞疫苗，通过皮下注射后能在人体内激活EBV特异CTL，从而实现对肿瘤细胞的有效识别及杀伤，具有良好的有效性及安全性。目前恒赛生物正在国内推动KSD-101的注册申报并筹备生产基地的建设。5.康哲引进一款白癜风新药。康哲药业宣布，旗下公司康哲美丽与Incyte公司就后者临床后期口服小分子JAK1抑制剂povorcitinib订立合作许可协议，应用于非节段型白癜风、化脓性汗腺炎（HS）、结节性痒疹（PN）、哮喘和慢性自发性荨麻疹等治疗。根据协议，康哲药业将拥有在中国大陆、香港、澳门、台湾及东南亚十一国开发及商业化的独家权利，以及在区域内生产产品的非独家许可权利。国际药讯1.AZ/第一三共ADC在美报sBLA。阿斯利康与第一三共开发的靶向TROP2的ADC药物Dato-DXd（Datopotamab deruxtecan）的生物制品许可申请（sBLA）获 FDA受理，用于治疗既往在不可切除或转移性疾病阶段接受过系统治疗的HR+、HER2-（IHC 0、IHC 1+ 或 IHC 2+/ISH-）的乳腺癌，PDUFA日期为明年1月。在 III期临床TROPION-Breast 01研究中，与化疗相比，Dato-DXd可将疾病进展或死亡风险显著降低37%。2.肿瘤疫苗结直肠癌临床积极。Gritstone bio公司个体化癌症疫苗GRANITE联合免疫检查点抑制剂及氟嘧啶/贝伐珠单抗一线维持治疗转移性微卫星稳定性结直肠癌患者的Ⅱ/Ⅲ期临床结果积极。与氟嘧啶/贝伐珠单抗相比，GRANITE组合显著改善了患者无进展生存期PFS（HR=0.82，95% CI：0.34-1.67），延长高危患者的PFS（HR=0.52，95% CI：0.15-1.38）；且药物总体耐受性良好。此前，该疫苗已获得FDA快速通道资格。3.Vistagen公司FIC社恐新药启动Ⅲ期临床。Vistagen公司潜在“first-in-class"鼻喷雾剂fasedienol（PH94B）启动评估急性治疗社交焦虑症（SAD）的Ⅲ期临床PALISADE-3试验。Fasedienol可调节与恐惧和焦虑密切相关的嗅觉-杏仁核神经回路，减弱交感神经自主神经系统的张力。在PALISADE-2试验中，PH94B治疗显著改善了患者的主观焦虑量表评分（-13.8分vs-8.0分），并显著提高了患者的临床应答率（40.6%vs18.6%）。蔼睦医疗拥有该产品在中国、韩国和东南亚地区的开发和商业化权益。4.FIC肾病抑制剂Ⅱ/Ⅲ期临床积极。Vertex公司潜在“first-in-class”小分子APOL1抑制剂inaxaplin（VX-147）治疗APOL1介导肾病（AMKD）患者的Ⅱ/Ⅲ期临床结果积极。独立的数据监查委员会（IDMC）已评估该项研究Ⅱ期部分的安全性及有效性数据，建议在Ⅲ期阶段部分选择inaxaplin（每日一次45mg）单一剂量；还建议扩展患者招募范围，纳入10至17岁的AMKD青少年患者。此前，该新药已获得FDA授予突破性疗法认定。5.Equillium公司CD6单抗早期临床积极。Equillium公司CD6单抗itolizumab治疗狼疮性肾炎患者的Ⅰb期临床EQUALIZE结果积极。Itolizumab可选择性靶向CD6-ALCAM信号通路，选择性抑制致病性效应T细胞，同时保留对维持平衡免疫反应至关重要的调节T细胞。第36周时，itolizumab治疗患者尿蛋白肌酐比值（UPCR）较基线降低73%；有37.5%患者达到完全缓解（UPCR≤0.7g/g），有43.8%患者达到部分缓解（UPCR≥50%）；且药物耐受性良好。6.Context公司实体瘤双抗报IND。Context公司CLDN6/CD3双抗CTIM-76向FDA提交了首次人体IND申请，计划开展Ⅰ期剂量递增和扩展研究，评估用于治疗Claudin 6（CLDN6）阳性妇科和睾丸癌患者的安全性、耐受性与初步疗效。CTIM-76结合了高选择性的CLDN6结合臂和CD3结合单链Fv结构域，其Fc被设计为功能性单价，以避免异常T细胞激活并提高安全性。CLDN6是许多实体瘤类型的有效治疗靶点，包括卵巢、子宫内膜、睾丸和胃。医药热点1.深圳首个国际联合临床研究所落户中山七院。近日，“伯明翰大学-中山七院联合临床研究所揭牌仪式暨临床研究国际合作论坛”在中山大学附属第七医院举办，中山七院与英国伯明翰大学联合建设的临床研究所正式宣布成立。这是深圳市成立的第一个国际联合临床研究所。中山七院是中山大学设置在深圳市的首家直属附属医院。医院规划总床位4000张。2.药明生物调整高管职位。药明生物宣布，自2024年3月31日起，周伟昌已退任公司首席技术官以及全球生物制药开发及运营总裁等职务，并调任为公司非执行董事及全球生物制药开发及运营名誉总裁及首席执行官高级顾问以支援公司的发展。调任后，周伟昌将留任董事会战略委员会成员，为公司的决策提供支持。此前，据1月15日药明生物的公告，药明生物欧美CMC管理负责人Sherry Gu将接任周博士职责，担任药明生物CTO及执行副总裁、生物制药开发及生产部负责人。3.印度CAR-T一针最低21.7万元。近日，《自然》杂志刊登一篇最新研究论文显示，印度生物技术公司ImmunoACT研发出一种经济实惠的CAR-T细胞疗法NexCAR19，其治疗费用仅为全球同类商业产品的十分之一，一次治疗费用只要3-4万美元（约合人民币21.7至28.9万元）。该疗法已于去年10月获得印度药品监管机构批准在印度用于治疗。评审动态 1. CDE新药受理情况（04月02日) 2. FDA新药获批情况（北美03月29日）股市资讯上个交易日 A 股医药板块 -0.77%涨幅前三跌幅前三冠福股份+10.04% 葵花药业 -6.62%海顺新材 +8.22% 大理药业 -6.53%江苏吴中 +7.04% 艾德生物 -5.74%【恩华医药】公司1类化学药品NH103草酸盐片获得《药物临床试验批准通知书》。【联环药物】公司咪达那新片获得药物临床试验批准通知书。【百利天恒】公司自主研发的创新生物药BL-M07D1相关的联合用药“BL-07D1+PD-1/PD-L1单抗±化疗”及“BL-M07D1+帕妥珠单抗土化疗”，近日收到国家药品监督管理局(NMPA)正式批准签发的《药物临床试验批准通知书》。【君实生物】公司产品昂戈瑞西单抗注射液(重组人源化抗PCSK9单克隆抗体注射液，产品代号:JS002)的两项新适应症上市申请已获得国家药品监督管理局受理。- The End -戳“阅读原文”，了解更多医药研发及股市资讯。

临床申请疫苗临床3期临床1期临床2期

2024-04-02

·BioSpace

Upstream Bio Announces Appointment of Rand Sutherland as CEO and Additions to Leadership Team

Mike Gray appointed as CFO and COO, Lisa Fiering joins as SVP, People & Culture WALTHAM, Mass.--(BUSINESS WIRE)-- Upstream Bio, a clinical-stage biotech company advancing verekitug (UPB-101) for respiratory disorders, today announced strategic leadership changes including the appointment of Rand Sutherland, MD, as Chief Executive Officer. Upstream has also appointed Mike Gray as Chief Financial Officer and Chief Operating Officer, and Lisa Fiering as Senior Vice President of People & Culture. These leadership changes will support the growth and evolution of Upstream as the company works to advance verekitug, a recombinant fully human immunoglobulin G1 monoclonal antibody which blocks the thymic stromal lymphopoietin receptor (TLSPR), in ongoing Phase 2 clinical trials for severe asthma and chronic rhinosinusitis with nasal polyps (CRSwNP). “I am thrilled to join Upstream Bio as CEO. I am committed to the company’s work to conquer inflammation at its source and intend to bring our team into the next stage of business and clinical operations,” said Dr. Sutherland. “Having dedicated much of my career to improving care for people living with asthma, I understand the substantial impact of severe respiratory diseases and I believe that verekitug could further improve standard of care for these patients. I am honored to lead this company at such an exciting time.” “Upstream Bio is at a critical period as the company advances verekitug, a potentially best-in-class therapeutic in the field of TSLP biology,” said Ron Renaud, Chair of the Board of Directors for Upstream Bio. “I want to thank Samantha Truex for serving as Upstream Bio’s CEO from launch through the initiation of our Phase 2 studies and leading the company to this juncture. By evolving and building our leadership team with these additions, we are further positioning Upstream Bio to become a leader in the immunotherapy landscape. I am pleased to welcome Rand, Mike and Lisa to the Upstream Bio team.” Dr. Sutherland joins Upstream Bio with more than 25 years of business and clinical experience, having most recently served as CEO of Seeker Biologics, and before that as President of Translate Bio prior to its acquisition by Sanofi. Previously, Dr. Sutherland held a number of R&D and medical affairs roles at Sanofi, providing leadership for the development of novel medicines in Immunology and Rare Diseases, and leading medical affairs globally for the Specialty Care business unit. Dr. Sutherland also serves as an independent director of Allakos, Krystal Biotech and Vanqua Bio. Before joining the biopharma industry, Dr. Sutherland was Professor of Medicine at the University of Colorado and Chief of Pulmonary and Critical Care Medicine at National Jewish Health in Denver. He earned an MD from the University of Chicago, after which he trained in Internal Medicine at UCSF and in Pulmonary and Critical Care Medicine at the University of Colorado. Mr. Gray has more than 25 years of public-private leadership experience and was most recently the CFO and COO of Carmot Therapeutics, where he helped to secure the company’s acquisition by Roche in 2024. Before this, he was CFO and COO of Imara and Arsanis, working with the leadership teams of each company in completing initial public offerings and building leading organizations. Mr. Gray previously held a number of leadership positions at Curis. Mr. Gray served on the Board of Directors of Therapeutics Acquisition Corporation, a special purpose acquisition corporation, through its merger with POINT Biopharma, which was subsequently acquired by Eli Lilly and Company in March 2024. He received his BS in business administration (accounting) from Bryant College and an MBA in corporate finance and entrepreneurial management from the F.W. Olin Graduate School of Business at Babson College. Ms. Fiering brings to Upstream 30 years of experience, having spent the past 20 years in various people and culture roles at life sciences companies including Genzyme, Ironwood Pharmaceuticals, Keryx and Trillium, where she developed a pragmatic approach to drive team effectiveness through talent and organizational development. Since 2022, she has provided strategic consulting to early-stage biotech companies, developing strategy and building the foundation for the people and culture function for these growing companies. Ms. Fiering earned her BA in Sociology from Ithaca College. About Upstream Bio Upstream Bio strives to reach the source of inflammation and conquer it, leveraging its team’s diverse industry experience to develop verekitug (UPB-101) to ease the burden of respiratory diseases. Verekitug is a clinical-stage monoclonal antibody that inhibits the TSLP receptor. TSLP is a validated target positioned upstream of multiple signaling cascades that affect a variety of immune cells pivotal to common and rare diseases. Upstream has completed a clinical trial in asthma with 32 weeks of observation which demonstrated compelling and sustained reductions in disease-related biomarkers and enabled the investigation of UPB-101 in ongoing Phase 2 trials of asthma and of CRSwNP that include extended dosing regimens of up to every 24 weeks. View source version on businesswire.com: Contacts Source: Upstream Bio View this news release online at:

临床2期高管变更IPO临床结果并购